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S U M M A R Y
Background: Rapid virological response (RVR) is now thought to be the strongest predictor of sustained
virological response (SVR) in hepatitis C virus (HCV) patients undergoing antiviral therapy. It can be used
as a guide to individualize treatment duration. The aim of this study was to assess the role of RVR in
tailoring the duration of treatment.
Methods: Patients with HCV genotype 3 infections were enrolled and treated with pegylated interferon
alfa-2a (PEG IFN alfa-2a) 180 mg/week and ribavirin. HCV RNA was analyzed at weeks 4, 12, 16, and 24.
Treatment duration was individualized on the basis of RVR. Patients who achieved RVR and who were
aged 40 years with a body mass index (BMI) 27 kg/m2 received 16 weeks of treatment (group A).
Patients who achieved RVR and were aged >40 years with a BMI >27 kg/m2, aged >40 years with a BMI
27 kg/m2, and aged 40 years with a BMI >27 kg/m2 received 24 weeks of treatment (group B).
Patients who did not achieve RVR but who achieved an early virological response (EVR; HCV PCR-
negative or 2 log drop in HCV RNA at week 12) were treated with 24 weeks of therapy (group C).
Results: SVR was observed in 86% in group A, 82.2% in group B, and 46.8% in group C. A difference was
observed in SVR for patients with and without RVR and receiving the standard duration of treatment
(82.2% vs. 46.8%, p < 0 .001). The results show that the rate of SVR is not inferior in those with RVR treated
with 16 weeks of therapy compared to 24 weeks (86% vs. 82.2%, p = 0.004).
Conclusions: RVR is useful to individualize the duration of treatment and to predict the treatment
outcome. A short treatment of 16 weeks is as effective as 24 weeks in HCV genotype 3 patients who
achieve RVR, who have a low BMI, and are younger in age.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatitis C virus (HCV) constitutes a major public health
issue in Pakistan, with 4.8% of people living with this virus.1 In
developing countries, the major problem is the poor socio-
economic situation of the patients.2 Pegylated interferon (PEG
IFN) and ribavirin are expensive and people have difﬁculty in
affording this therapy. Therefore early detection of virological
failure helps to reduce additional costs and the adverse effects
of infective therapy. Moreover, a rapid virological response
(RVR; PCR-negative at week 4 of therapy) best predicts a
sustained virological response (SVR). It can be used as a guide
to individualize the duration of treatment. An individualized* Corresponding author. Tel.: +92 3 004852451.
E-mail address: gill95res@gmail.com (U. Gill).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.05.012treatment approach improves cost-effectiveness of HCV anti-
viral therapy by decreasing side effects and the cost of
therapy.3
HCV genotype is an important predictor of treatment
response, therefore the duration of treatment for HCV is based
on HCV genotype: 24 weeks is recommended for genotypes 2
and 3, and 48 weeks for genotypes 1 and 4.4,5 Preliminary
clinical data have shown that a shorter course of therapy is as
effective as a 24-week treatment regimen for patients with
HCV genotype 2 or 3, especially those with RVR.6–9 However, it
is important to determine whether these results are applicable
to other populations.
The most prevalent HCV genotype in the Pakistani population is
type 3, which has a favorable response to interferon.10 The primary
aim of this prospective cohort study was to evaluate whether a 16-
week regimen of PEG IFN and ribavirin is sufﬁcient to achieve SVR
among patients who achieve RVR.ses. Published by Elsevier Ltd. All rights reserved.
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2.1. Patient selection
Treatment-naı¨ve HCV genotype 3 patients aged >16 years,
males and females, were enrolled in the study using the following
criteria: anti-HCV antibody-positive and positive PCR for HCV RNA
detection. Furthermore the patients had to be negative for
hepatitis B surface antigen and not suffering from decompensated
liver disease or autoimmune disorders; they also had to have no
history of depression or cardiac diseases.
Prior to starting treatment, the patient’s complete blood
count, prothrombin time, alanine aminotransferase (ALT),
quantitative HCV RNA, and genotype were determined. All
patients in the study were required to have a hemoglobin level
above 13 g/dL in men and 12 g/dL in women, a white blood cell
count greater than 3  109/L, and a platelet count greater than
100  109/L. Normal levels of serum albumin and normal thyroid
function tests were also required. Patients who were under 16
years or above 70 years of age and pregnant women were
excluded from the study.
2.2. Study design
This study was conducted at Maroof International Hospital
from May 2009 to June 2011. The protocol was approved by the
ethics review committee of the hospital and informed written115 patients  received
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Figure 1. Flow diagram of patient enrollment, and disconsent was obtained from all of the participants. The study
was designed by the Digestive Disease Study Group of Maroof
International Hospital. A total of 495 patients were screened.
Among them 485 fulﬁlled the study criteria and were enrolled
for antiviral therapy. Therapy was started with PEG IFN alfa-2a
180 mg weekly and ribavirin 400 mg twice daily. The treatment
duration was individualized on the basis of qualitative HCV
analysis at week 4 after the start of treatment. Patients who
were HCV PCR-negative at week 4 were allocated to one of two
groups (group A, group B). Patients who achieved RVR and who
were aged 40 years with a BMI 27 kg/m2 received 16 weeks
of treatment (group A). Patients who achieved RVR and who
were aged >40 years with BMI >27 kg/m2, aged >40 years with
BMI 27 kg/m2, and aged 40 years with BMI 27 kg/m2
received 24 weeks of treatment (group B). Patients who did not
achieve RVR but who achieved an early virological response
(EVR; HCV PCR-negative or 2 log drop in HCV RNA at week
12) were treated with 24 weeks of therapy (group C). Patients
with a <2 log drop in viral load at week 12 were considered
non-responders and the therapy was discontinued. All of the
patients were followed up for 24 weeks after the end of therapy
(Figure 1).
2.3. Measurement of HCV RNA and HCV genotype
Serum HCV RNA levels were evaluated quantitatively by real-
time PCR (Rotor-Gene 3000, Corbet Research; 50 IU/ml) at baseline,109 pat ients 
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Table 1
Basic characteristics of the 460 patients who completed treatment in this study
Characteristics All patientsPatients with RVRWith No RVR
Sex
Male 210 153 (72.8%) 57 (27.1%)
Female 250 198 (79.2%) 52 (20.8%)
Age, years
40 236 195 (82.6%) 41 (17.3%)
>40 224 156 (69.6%) 68 (30.3%)
Viral load, IU/ml
8  105 185 150 (81.0%) 35 (18.9%)
>8  105 275 201 (73.0%) 74 (26.9%)
ALT
Normal 97 76 (78.3%) 21 (21.6%)
Raised 368 275 (74.7%) 88 (23.9%)
BMI, kg/m2
27 335 260 (77.6%) 75 (22.4%)
>27 125 91 (72.8%) 34 (27.2%)
Route of transmission
Dentist 157 117 (74.52%) 40 (25.47%)
Blood transfusion 10 7 (7%) 3 (30%)
Unsterilized surgical instrument 72 47 (65.27%) 28 (38.8%)
Unknown source 76 60 (79%) 16 (21%)
RVR, rapid virological response; ALT, alanine aminotransferase; BMI, body mass
index.
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treatment. HCV genotyping was performed using the Invader HCV
genotyping assay developed by Third Wave Technologies, Inc.11
2.4. Assessment of efﬁcacy
The primary end-point of this study was to assess SVR, which
is deﬁned as undetectable HCV RNA at 6 months after the end of
treatment; non-responders were those who had a <2 log drop in
HCV RNA at week 12 of treatment. RVR is deﬁned as undetectable
HCV RNA at 4 weeks of treatment. Patient relapse was deﬁned as
reappearance of HCV RNA during the follow-up period in
patients who had achieved negative HCV RNA at the end of
treatment.
2.5. Statistical analysis
Data were analyzed using SPSS version 15 for windows (SPSS
Inc., Chicago, IL, USA). The results for all variables are given in the
form of the rate (%). The Pearson Chi-square method was used to
measure variable associations with the likelihood of achieving SVR.
A p-value below 0.05 was considered signiﬁcant. Multivariate
logistic regression analysis was performed to identify factors
associated with a response to therapy. Variables with associations
in the univariate analysis were entered into the multivariate
logistic regression analysis to identify independent predictors of
treatment outcome.
3. Results
Four hundred and ninety-ﬁve patients suffering from HCV
genotype 3 infections were recruited from May 2009 to June 2011.
Of these, 460 completed treatment; 210 (45.6%) were male and 250
(54.3%) were female. Adverse events resulting in patients dropping
out at week 4 included rash, headache, fatigue, and emotional
instability. Moreover one patient withdrew from treatment at
week 22 due to anemia. Overall, RVR was achieved in 351 (76.3%)
patients. The characteristics of the study patients are presented in
Table 1.
Overall, SVR was achieved in 344 (74.8%) patients. The SVR rate
observed in group A was 86% (99 patients), in group B was 82.2%
(194 patients), and in group C was 46.8% (51 patients), as shown in
Figures 2 and 3. SVR rates were compared between group BPatien ts with 
RVR
n 
HCV-3
n = 351
Group B
Group A
Figure 2. Predictability of SVR in the 16-week patients (those who achieved RVR and had 24 weeks of treatment)
and group C patients (those who did not achieve RVR and received
24 weeks of treatment). These patients were re-assessed at week
12 and we did not ﬁnd any patient who met the criteria for a non-
responder. However, SVR rates were signiﬁcantly higher in group
B patients (24 weeks of treatment) who had RVR as compared to
group C patients (24 weeks of treatment) who did not have RVR:
82.2% vs. 46.8%, p < 0.001. Moreover result shows that the rate of
SVR is not inferior in those with RVR treated with 16 weeks of
therapy compared to 24 weeks of therapy (86% vs 82.2%,
p = 0.004).
3.1. Predictors of a sustained virological response
Both pretreatment and treatment factors that could be
associated with the response to the therapeutic regimen were
compared between patients with and without SVR. The prelimi-
nary analysis showed that rates of SVR were higher in patients
aged 40 years as compared to patients aged >40 years (82.6% vs.
66.5%, p < 0.0001). We did not ﬁnd a signiﬁcant difference for SVR= 11 5
n = 23 6
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Figure 3. Predictability of SVR in the 24-week treatment group without RVR.
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categorized into two levels: low level (8  105 IU/ml) and high
level (>8  105 IU/ml). The response rate to treatment varied as
the viral load increased. Patients with a pretreatment viral load of
8  105 IU/ml were compared to those with a pretreatment viral
load of >8  105 IU/ml: 83.5% vs. 46.8%, p < 0.0001. RVR had a high
predictive value for achieving SVR; 83.5% (293/351) of patients
with undetectable HCV RNA at week 4 had undetectable HCV RNA
at follow-up (24 weeks after treatment completion). Most of the
patients (n = 363) were in the raised ALT group. We did not observe
a difference in SVR between the normal ALT group and the raised
ALT group (74.2% vs. 74.9%).
Factors with signiﬁcant associations in the univariate analysis
were further analyzed by multivariate logistic regression. Accord-
ing to the multivariate logistic regression analysis, age 40 years
(adjusted odds ratio (OR) 1.7, 95% conﬁdence interval (CI) 1.036–
2.916, p < 0.001), RVR (adjusted OR 6.32, 95% CI 3.79–10.55,
p < 0.001), pretreatment viral load 8  105 IU/ml (adjusted OR
3.09, 95% CI 1.747–5.46, p < 0.001), and BMI 27 kg/m2 (adjusted
OR 1.73, 95% CI 0.98–3.124, p = 0.05) were independently
associated with achieving SVR (Figure 4).
3.2. Adverse events
The incidence of side effects in the 16-week treatment group
was similar to that in the 24-week treatment group. Adverse
events in the two groups included fatigue, headache, and an
inﬂuenza-like syndrome. Most of the patients experienced fever
because interferon raises the body temperature. Fortunately these
symptoms tend to lessen after the ﬁrst few weeks of therapy.
Hemoglobin levels decreased in the ﬁrst few weeks and returned to
normal within a few weeks of completion of treatment. However
alopecia cases were seen only in the 24-week treatment group
(Figure 4).Figure 4. Multiple logistic regression model to predict SVR.4. Discussion
The gold standard treatment for chronic hepatitis C (CHC)
patients is PEG IFN in combination with ribavirin. Being
expensive and requiring a long treatment duration, this therapy
imposes a huge economic burden on the economy of a
developing country such as Pakistan. A signiﬁcant proportion
of the Pakistani population (approximately 10 million) is
infected with this virus.12 In Pakistan, HCV genotype 3 is highly
prevalent.13 The standard therapy for HCV genotypes 2 and 3 is
24 weeks of PEG IFN in combination with ribavirin. For these
reasons it is important to tailor the duration of treatment. RVR
may be an important landmark for determining the duration and
outcome of treatment.14–16 The assessment of Dalgard and
Mangia is in favor of 16 weeks of therapy for patients with HCV
genotype 2 infection,17 however there is no such recommenda-
tion for genotype 3. In this study, we showed that a shorter
course of 16 weeks of PEG IFN alfa-2a and ribavirin 400 mg twice
a day is as effective as a standard 24-week course in the Pakistani
population infected with chronic HCV genotype 3, who achieved
RVR at week 4.
In this study, the observed overall SVR to PEG IFN alfa-2a plus
ribavirin therapy was 74.8%. This is higher when compared with
the response rate predicted by Rumi et al. (65%) and that predicted
by Shiffman et al. (70%).18,19 A number of viral and host factors
have been found to modulate the response to antiviral treatment.
In agreement with previous studies,20,21 the multivariate analysis
revealed younger age, lower baseline viral loads, lower BMI, and
RVR to be independent predictors of SVR.
Numerous studies have documented that females respond
better to IFN therapy than males, but our study showed that the
overall rate of successful responses to therapeutic regimens was
higher in males; however the difference was not statistically
signiﬁcant (female 74.2% vs. male 75.5%, p = 0.75). Our study
further showed that among females, age was also an important
factor with regard to therapy response. Women aged 40 years
had a better response to standard treatment compared to women
aged >40 years (40 years vs. > 40 years, 84.7% vs. 65.2%). Hayashi
correlated estrogen hormone with a better response in younger
women and strongly suggest that estrogen may enhance the
efﬁcacy of IFN therapy.22 Moreover some reports have described
that aging leads to a decline in the ability of the immune system to
protect the host from pathogens due to a reduction in naı¨ve
T-cells.23,24
Several studies have revealed that there is an inverse
relationship between pretreatment viral load and SVR.25,26 Our
data support this ﬁnding to some extent, because there was a
signiﬁcantly lower risk of relapse of SVR after 16 weeks among
patients with a pretreatment viral load 8  105 IU/ml compared
to those with a high viral load (3.8 vs. 24.3, p = 0.001).
In our study 351 (76.3%) patients with HCV genotype 3
attained RVR, while 109 did not achieve RVR. The failure of
attaining RVR may be due to replication of drug resistance
variants, which may develop by selective pressure of drug
therapy.27 Among RVR patients, the risk of viral relapse was
16.5%, and 83.5% of them eradicated the virus. In agreement with
Puoti et al.,28who reported rates of RVR and SVR in HCV genotype
3 patients of 64% and 82%, respectively, our study also showed
the SVR rate achieved in RVR patients to be higher as compared to
the rate achieved in patients who did not have RVR (88.3% vs.
63.6%, p < 0.001), showing that RVR is a strong predictor of
SVR.29 It also suggests that the week-4 virological response is a
useful guide for treatment duration in HCV genotype 3 infection.
Shortening the treatment period for chronic HCV infection is of
major importance because this will reduce the costs for both
patients and society.
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in patients with HCV genotypes 2 and 3 results in a higher relapse
rate than in patients treated for 24 weeks.18,19 In contrast to these
studies, our results revealed that SVR was almost equal among
patients who achieved RVR with a short treatment duration and
with a 24-week duration (82.2% vs. 86%). These data are consistent
with data reported by other authors6,7 and suggest that a short
treatment regimen is as effective as a 24-week regimen for patients
with HCV genotypes 2 and 3, especially those with RVR. Further
prospective studies with larger numbers of patients are necessary
to assess whether the standard treatment duration (24 weeks) and
the short treatment duration (16 weeks) produce equal outcomes
in genotype 3 patients. This study will also help to establish
guidelines for short treatment regimens for genotype 3-infected
patients who have the ability to achieve SVR.
In conclusion, monitoring the viral response in treatment-naı¨ve
patients with chronic hepatitis C may be useful to individualize
treatment duration. Patients with a high sensitivity to PEG IFN
showing rapid decreases in viral kinetics may be selected and
safely treated for a shorter period of time than in the past.
Shortening the treatment duration to 16 weeks may be sufﬁcient in
Pakistani patients with HCV genotype 3 who have achieved RVR,
have a low BMI, and who are younger in age.
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